FOSTER CITY, CA -- (MARKET WIRE) -- January 23, 2007 -- Entelos, Inc. (LSE: ENTL), a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today the completion of its Cardiovascular PhysioLab® platform, a comprehensive large-scale computer simulation of cholesterol regulation, atherogenesis, and cardiovascular risk. This newly developed platform enables Entelos to rapidly assess novel drug targets, evaluate combination therapies, identify and interpret biomarker patterns, and predict a drug's long-term clinical efficacy in managing cholesterol, atherosclerosis, and heart disease. The company is already conducting research in partnership with three big pharmaceutical customers using this platform.
